Bronchiectasis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 63 pages report, published by Global Markets Direct

Keywords : Bronchiectasis Therapeutic Products under Development, Key Players in Bronchiectasis Therapeutics, Bronchiectasis Pipeline Overview, Bronchiectasis Pipeline, Bronchiectasis Pipeline Assessment

Report ThumbnailSeptember-2013
Bronchiectasis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bronchiectasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bronchiectasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiectasis. Bronchiectasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchiectasis.
- A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchiectasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Bronchiectasis, H2 2013 8
  • Products under Development for Bronchiectasis - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Mid Clinical Stage Products, H2 2013 12
  • Early Clinical Stage Products, H2 2013 13
  • Pre-Clinical Stage Products, H2 2013 14
  • Assessment by Monotherapy Products, H2 2013 25
  • Assessment by Route of Administration, H2 2013 26
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Molecule Type, H2 2013 28
  • Assessment by Stage and Molecule Type, H2 2013 29
  • List of Tables
  • Number of Products Under Development for Bronchiectasis, H2 2013 8
  • Products under Development for Bronchiectasis - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
  • Products under Development by Companies, H2 2013 15
  • Aradigm Corporation, H2 2013 16
  • AstraZeneca PLC, H2 2013 17
  • Gilead Sciences, Inc., H2 2013 18
  • Chiesi Farmaceutici SpA, H2 2013 19
  • Bayer AG, H2 2013 20
  • Kamada Ltd., H2 2013 21
  • Nostrum Pharmaceuticals, LLC, H2 2013 22
  • Savara, Inc., H2 2013 23
  • Clarassance, Inc., H2 2013 24
  • Assessment by Monotherapy Products, H2 2013 25
  • Assessment by Stage and Route of Administration, H2 2013 27
  • Assessment by Stage and Molecule Type, H2 2013 29
  • Bronchiectasis Therapeutics - Drug Profile Updates 46
  • Bronchiectasis Therapeutics - Discontinued Products 53
  • Bronchiectasis Therapeutics - Dormant Products 54
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Bronchiectasis Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Bronchiectasis 8
  • Bronchiectasis Therapeutics under Development by Companies 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Mid Clinical Stage Products 12
  • Comparative Analysis 12
  • Early Clinical Stage Products 13
  • Comparative Analysis 13
  • Pre-Clinical Stage Products 14
  • Comparative Analysis 14
  • Bronchiectasis Therapeutics - Products under Development by Companies 15
  • Companies Involved in Bronchiectasis Therapeutics Development 16
  • Aradigm Corporation 16
  • AstraZeneca PLC 17
  • Gilead Sciences, Inc. 18
  • Chiesi Farmaceutici SpA 19
  • Bayer AG 20
  • Kamada Ltd. 21
  • Nostrum Pharmaceuticals, LLC 22
  • Savara, Inc. 23
  • Clarassance, Inc. 24
  • Bronchiectasis - Therapeutics Assessment 25
  • Assessment by Monotherapy Products 25
  • Assessment by Route of Administration 26
  • Assessment by Molecule Type 28
  • Drug Profiles 30
  • ciprofloxacin - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • ciprofloxacin - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • ciprofloxacin liposomal - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • AZD-5069 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • aztreonam - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • vancomycin - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • CG-1011 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • Neutrophil Elastases Inhibitors - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • dapsone - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • B1-AAT - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • BAY-858501 - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • Bronchiectasis Therapeutics - Drug Profile Updates 46
  • Bronchiectasis Therapeutics - Discontinued Products 53
  • Bronchiectasis Therapeutics - Dormant Products 54
  • Bronchiectasis - Product Development Milestones 55
  • Featured News & Press Releases 55
  • Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 55
  • Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product 56
  • Apr 24, 2013: Pharmaxis's Phase III Clinical Trial With Bronchitol Fails To Meet Primary Endpoint 56
  • Mar 08, 2013: Pharmaxis Announces Completion Of Phase III Trial Of Bronchitol For Treatment Of Bronchiectasis 57
  • Sep 27, 2012: Pharmaxis Receives Maximum Extension Of Term For Bronchitol Patent In Germany 58
  • Sep 18, 2012: Aradigm Receives New US Composition Of Matter Patent For Pulmaquin 58
  • Aug 23, 2012: Bayer HealthCare Initiates Phase III Study Of Ciprofloxacin Dry Powder For Inhalation To Treat Non-Cystic Fibrosis Bronchiectasis 59
  • Mar 12, 2012: Aradigm Receives FDA Clearance For Phase III Clinical Trial Of Pulmaquin In Patients With Non-Cystic Fibrosis Bronchiectasis 60
  • Feb 21, 2012: Aradigm Receives US Patent Covering Its Lead Preparation Pulmaquin 60
  • Dec 13, 2011: Pharmaxis Announces Phase III Study Results Of Bronchitol For Treatment Of Bronchiectasis 61
  • Appendix 62
  • Methodology 62
  • Coverage 62
  • Secondary Research 62
  • Primary Research 62
  • Expert Panel Validation 62
  • Contact Us 63
  • Disclaimer 63

Please select a license type

Share

Related Products

Global Markets DirectBronchiectasis - Pipeline Review, H2 2013Product ThumbnailBronchiectasis - Pipeline Review, H2 2013, Industry ReportProduct #: 113295
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved